Luckwel Pharmaceuticals (LWEL) 10-Q2020 Q1 Quarterly report

Filed: 14 Aug 19, 4:36pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: active, activity, adjusted, alternative, approach, asset, assumption, average, bank, basic, begun, Boston, broker, calculated, candidate, carryover, categorization, chargeable, classification, classified, Codification, computed, conformity, dealer, decreased, deferred, determined, determining, diluted, dilutive, disease, diverting, dividing, enacted, evasion, evidence, examination, fewer, forward, gastrointestinal, hierarchy, Houston, identical, Inland, input, integral, investment, largest, Launch, length, liability, located, lowest, make, malarial, maturity, measure, measured, measurement, measuring, method, Nevada, oncological, open, orderly, paid, part, pipeline, prevailing, previously, prior, priority, proper, provision, pursue, quoted, recognition, recognized, recognizing, recoverability, refer, referred, registered, remain, renewable, renewed, resolution, rheumatic, rheumatoid, salary, settlement, significant, spent, statute, step, stromal, sustained, term, terminated, transparency, unable, uncertainty, underpayment, unobservable, USD, valuation, Waltham, weight, weighted

Removed: aggregating, application, apply, approximately, ASU, audited, beginning, behalf, Bulletin, comprehensive, consummated, continuing, controlling, duty, eliminate, event, executed, family, FASB, February, guidance, HKD, increased, Instrument, law, Li, Lijian, long, made, newly, Note, payment, permitted, public, receiving, reclassification, recurring, relate, rent, require, resulting, retained, sharply, sister, source, stamp, stranded, underlying, view

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

LWEL similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Luckwel Pharmaceuticals Inc. (the “Company”) on Form 10-Q for the three months ended June 30, 2019 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Kingrich Lee, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

August 14, 2019	/s/ Kingrich Lee,
	Kingrich Lee
	Chief Executive Officer and Chief Financial Officer(Principal Executive Officer and Principal Accounting and Financial Officer)